41 results on '"Roobol, Monique J."'
Search Results
2. VALIDATION OF A RISK CALCULATOR PREDICTING BIOPSY OUTCOME IN PROSTATE CANCER TREATED WITH ACTIVE SURVEILLANCE: PD08-04
3. CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC.: PD09-01
4. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
5. A Framework for the Identification of Men at Increased Risk for Prostate Cancer
6. Prevalence, Treatment Modalities and Prognosis of Familial Prostate Cancer in a Screened Population
7. A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial
8. Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
9. Do Anxiety and Distress Increase During Active Surveillance for Low Risk Prostate Cancer?
10. HEAD TO HEAD COMPARISON OF THE ERSPC RISK CALCULATOR AND ANN PROSTATACLASS IN 4685 PATIENTS FOR PROSTATE CANCER RISK ON BIOPSY: 1982
11. Reply by Authors
12. PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007.: 1792
13. SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION.: 648
14. ANXIETY AND DISTRESS DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: A LONGITUDINAL ANALYSIS: 498
15. ANXIETY AND DISTRESS DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: A LONGITUDINAL ANALYSIS: 498
16. Defining Increased Future Risk for Prostate Cancer: Evidence From a Population Based Screening Cohort
17. 4-YEAR PROSTATE SPECIFIC ANTIGEN PROGRESSION AND DIAGNOSIS OF PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM
18. THE USE OF -2proPSA AND BPSA IN PROSTATE CANCER DETECTION: EXTERNAL CROSS-VALIDATION OF A PREDICTIVE MODEL: 2049
19. PROSTATE CANCER (PC) IN MEN PRESENTING WITH PSA <3.0 NG/ML – DETECTION AT RE-SCREENING AND AS INTERVAL CANCERS DURING A 12-YEAR PERIOD: 1881
20. THE CLINICAL IMPACT OF THE PSA ASSAY WHO CALIBRATION ON PROSTATE BIOPSY RATES AND PROSTATE CANCER DETECTION: 1757
21. VALUE OF PSA VELOCITY FOR PREDICTING BIOPSY OUTCOME IN PREVIOUSLY SCREENED MEN PARTICIPATING IN THE EUROPEAN RANDOMIZED STUDY OF PROSTATE CANCER SCREENING (ERSPC): 1756
22. OVERALL VERSUS DISEASE-SPECIFIC SURVIVAL OF SCREEN- DETECTED PROSTATE CANCER PATIENTS WHO WERE INITIALLY MANAGED EXPECTANTLY: 430
23. PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESS
24. Editorial Comment
25. INDEPENDENT REPLICATION OF A FOUR KALLIKREIN PANEL TO DETECT PROSTATE CANCER: DATA FROM THE EUROPEAN RANDOMIZED STUDY OF PROSTATE CANCER SCREENING IN ROTTERDAM, NETHERLANDS
26. PROSPECTIVE PROTOCOL BASED ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: SHORT-TERM RESULTS OF 500 PATIENTS IN THE PRIAS STUDY
27. 2125 ANTIBIOTIC PROPHYLAXIS IN TRANSRECTAL PROSTATE BIOPSY: CIPROFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE
28. 2033 DISEASE-SPECIFIC SURVIVAL IN MEN WITH INTERVAL CANCERS COMPARED TO MEN WITH CANCERS IN THE CONTROL ARM: LONG-TERM RESULTS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC)-ROTTERDAM
29. 2028 “ESCAPES”-MEN WHO DEVELOP METASTASIS AND/OR DIE FROM PROSTATE CANCER DESPITE SCREENING-: LONG-TERM RESULTS FROM THE ERSPC, SECTION ROTTERDAM
30. 1922 COMPARISON OF RISK CALCULATORS FROM THE PROSTATE CANCER PREVENTION TRIAL AND THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER IN A CONTEMPORARY CANADIAN COHORT
31. METASTASIS-FREE SURVIVAL IN SCREEN AND CLINICAL DETECTED PROSTATE CANCER: A COMPARISON BETWEEN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER AND NORTHERN IRELAND
32. MISSING A PROSTATE CANCER LESION DURING HISTOLOGICAL EXAMINATION OF PROSTATE BIOPSY: CHARACTERISTICS AND FOLLOW-UP IN A SCREENED COHORT
33. DEFINING MEN AT INCREASED RISK OF DEVELOPING PROSTATE CANCER: EVIDENCE FROM A POPULATION-BASED SCREENING COHORT
34. 1881: Comparison of the Number and Characteristics of Prost Ate Cancer Interval Cases in a Screening Study Using a 2-YEAR or 4-Year Screening Interval
35. 1757: How to Screen for Prostate Cancer in 2007 - Detection and Characteristics in men age 55 - 74, in men with PSA Levels Less than 3 ng/ml, 4 and 8 Years after the Initial Screening (Erspc Rotterdam)
36. 1612: Use of Total PSA, Free PSA, %FPSA, and HK2 Measurements to Predict Occurrence of Prostate Cancer at Biopsy. ERSPC Rotterdam
37. Editorial comment
38. 1270: Randomized Double-Blind, Placebo-Controlled,Crossover Study of Men with Prostate Cancer and Rising PSA: Effectiveness of a Dietary Supplement
39. 623: Four Year Prostate Specific Antigen (PSA) Progression and Prostate Cancer Detection in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Section Rotterdam
40. 621: Final Results of the Initial and Second Prostate Cancer Screening Round of the European Randomized Study of Screening for Prostate Cancer (ERSPC, Section Rotterdam)
41. 448: Prostate Cancer Detection and PSA Increaseafter 4 Years in Dutch and Japanese Males Without Evidence of Disease at Initial Screening
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.